Pete Stavropoulos
Stock Analyst at Cantor Fitzgerald
(3.70)
# 769
Out of 4,712 analysts
43
Total ratings
39.53%
Success rate
12.37%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Pete Stavropoulos
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARCT Arcturus Therapeutics Holdings | Reiterates: Overweight | n/a | $17.02 | - | 5 | Dec 16, 2024 | |
| KALV KalVista Pharmaceuticals | Reiterates: Overweight | n/a | $8.53 | - | 1 | Dec 9, 2024 | |
| ALEC Alector | Reiterates: Overweight | n/a | $1.78 | - | 5 | Nov 26, 2024 | |
| ANNX Annexon | Reiterates: Overweight | n/a | $5.19 | - | 9 | Nov 15, 2024 | |
| VSTM Verastem | Reiterates: Overweight | n/a | $3.71 | - | 1 | Oct 18, 2024 | |
| VERA Vera Therapeutics | Reiterates: Overweight | $107 | $41.41 | +158.39% | 7 | Oct 3, 2024 | |
| PLRX Pliant Therapeutics | Reiterates: Overweight | n/a | $13.56 | - | 4 | Aug 8, 2024 | |
| DNTH Dianthus Therapeutics | Initiates: Overweight | n/a | $22.74 | - | 1 | Jun 27, 2024 | |
| JSPR Jasper Therapeutics | Reiterates: Overweight | n/a | $22.25 | - | 4 | Jun 18, 2024 | |
| RZLT Rezolute | Reiterates: Overweight | $5 | $4.96 | +0.81% | 3 | Sep 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $13 | $1.78 | +630.34% | 2 | Jul 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $8 | $10.54 | -24.10% | 1 | Mar 20, 2023 |
Arcturus Therapeutics Holdings
Dec 16, 2024
Reiterates: Overweight
Price Target: n/a
Current: $17.02
Upside: -
KalVista Pharmaceuticals
Dec 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $8.53
Upside: -
Alector
Nov 26, 2024
Reiterates: Overweight
Price Target: n/a
Current: $1.78
Upside: -
Annexon
Nov 15, 2024
Reiterates: Overweight
Price Target: n/a
Current: $5.19
Upside: -
Verastem
Oct 18, 2024
Reiterates: Overweight
Price Target: n/a
Current: $3.71
Upside: -
Vera Therapeutics
Oct 3, 2024
Reiterates: Overweight
Price Target: $107
Current: $41.41
Upside: +158.39%
Pliant Therapeutics
Aug 8, 2024
Reiterates: Overweight
Price Target: n/a
Current: $13.56
Upside: -
Dianthus Therapeutics
Jun 27, 2024
Initiates: Overweight
Price Target: n/a
Current: $22.74
Upside: -
Jasper Therapeutics
Jun 18, 2024
Reiterates: Overweight
Price Target: n/a
Current: $22.25
Upside: -
Rezolute
Sep 19, 2023
Reiterates: Overweight
Price Target: $5
Current: $4.96
Upside: +0.81%
Jul 17, 2023
Reiterates: Overweight
Price Target: $13
Current: $1.78
Upside: +630.34%
Mar 20, 2023
Reiterates: Overweight
Price Target: $8
Current: $10.54
Upside: -24.10%